Checkpoint Therapeutics Inc (OQ:CKPT)

Business Focus: Biotechnology & Medical Research

Apr 26, 2024 04:56 pm ET

Robbins LLP Reminds Stockholders of CKPT to Contact the Law Firm for Information About the Checkpoint Therapeutics, Inc. Class Action Lawsuit

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) securities between March 10, 2021 and December 15, 2023....

Apr 26, 2024 01:30 pm ET

CKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud Lawsuit

BENSALEM, Pa., April 26, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT).

Apr 26, 2024 01:30 pm ET

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Apr 26, 2024 01:08 pm ET

CKPT SHAREHOLDER ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CKPT

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class Period”), of the important June 4, 2024 lead plaintiff deadline.

Apr 25, 2024 12:07 pm ET

DEADLINE ALERT for HRT, CKPT, and SOND: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....

Apr 24, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Checkpoint, Sonder, and Perion and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), Sonder Holdings Inc. (NASDAQ:...

Apr 24, 2024 06:45 pm ET

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Apr 24, 2024 01:29 pm ET

DEADLINE ALERT for HRT, CKPT, SOND, QDEL: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....

Apr 24, 2024 11:29 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – CKPT

Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) and certain officers. The class action, filed in the United States District Court for the...

Apr 24, 2024 10:50 am ET

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. (“Checkpoint” or “the Company”) (NASDAQ: CKPT) for for violations of §§10(b) and 20(a) of the...

Apr 23, 2024 10:15 am ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

LOS ANGELES, April 23, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ: CKPT) for for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Apr 23, 2024 07:30 am ET

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) and reminds investors of the June 4, 2024 deadline to seek the role...

Apr 22, 2024 03:16 pm ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Checkpoint Therapeutics, Inc. (CKPT)

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 4, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Checkpoint Therapeutics, Inc....

Apr 22, 2024 11:00 am ET

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or “the Company”) (NASDAQ: CKPT) and...

Apr 22, 2024 07:00 am ET

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Apr 21, 2024 12:12 pm ET

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CKPT

Apr 21, 2024 07:00 am ET

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Apr 20, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ventyx Biosciences, Inc. (NASDAQ: VTYX), Anavex Life Sciences Corp. (NASDAQ:...

Apr 20, 2024 11:00 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPT

NEW YORK, April 20, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 24-cv-02613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Checkpoint securities between March 10, 2021 and December 15, 2023, both dates inclusive (the "Class Period"), seeking to recover

Apr 19, 2024 02:38 pm ET

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPT

NEW YORK, April 19, 2024 /PRNewswire/ --

Apr 19, 2024 07:00 am ET

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Apr 18, 2024 09:00 am ET

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

NEW YORK, April 18, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT) and reminds investors of the June 4, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Apr 18, 2024 08:00 am ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Apr 17, 2024 06:22 pm ET

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CKPT

Apr 17, 2024 12:07 pm ET

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Checkpoint Therapeutics, Inc. (CKPT) Investors

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ:

Apr 17, 2024 07:30 am ET

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

Apr 16, 2024 10:15 pm ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Apr 16, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, Checkpoint, and Sonder and Encourages Investors to Contact the Firm

Apr 16, 2024 01:50 pm ET

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Apr 16, 2024 12:00 pm ET

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Checkpoint Therapeutics, Inc. (CKPT) Investors

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ:

Apr 16, 2024 11:29 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – CKPT

Apr 15, 2024 05:14 pm ET

CKPT Class Action Alert: Robbins LLP Reminds Stockholders of Checkpoint Therapeutics, Inc. Class Action

Apr 15, 2024 01:00 pm ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT) for for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Apr 15, 2024 12:07 pm ET

DEADLINE ALERT for HRT, CKPT, and SOND: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Apr 15, 2024 11:00 am ET

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Apr 15, 2024 11:00 am ET

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, April 15, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ: CKPT) and certain of its officers.

Apr 15, 2024 11:00 am ET

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Checkpoint Therapeutics, Inc. (CKPT) Investors

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) securities between March 10, 2021 and December 15, 2023, inclusive (the “Class Period”). Checkpoint investors have until June 4, 2024 to f

Apr 15, 2024 09:30 am ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

LOS ANGELES, April 15, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ: CKPT) for for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Apr 13, 2024 08:00 pm ET

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT) for for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Apr 12, 2024 09:23 pm ET

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPT

NEW YORK, April 12, 2024 /PRNewswire/ --

Apr 12, 2024 09:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm

Apr 12, 2024 04:00 pm ET

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of Investors

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ:

Apr 12, 2024 01:10 pm ET

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) investors concerning the Company’s possible violations of federal securities laws.

Apr 12, 2024 10:30 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPT

NEW YORK, April 12, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 24-cv-02613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Checkpoint securities between March 10, 2021 and December 15, 2023, both dates inclusive (the "Class Period"), seeking to recover

Apr 12, 2024 10:20 am ET

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

Apr 12, 2024 05:00 am ET

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT) for for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Apr 12, 2024 04:30 am ET

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Apr 11, 2024 06:44 pm ET

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CKPT

Apr 11, 2024 02:00 pm ET

Checkpoint Therapeutics, Inc. Stockholder Alert: Robbins LLP Reminds Investors of the CKPT Class Action

Apr 11, 2024 03:30 am ET

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / April 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT) for for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Apr 10, 2024 05:52 pm ET

Checkpoint Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; June 4, 2024 deadline.

The Portnoy Law Firm advises Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) investors that a lawsuit was filed on behalf of investors that purchased Checkpoint securities between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class...

Apr 10, 2024 03:02 pm ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Apr 10, 2024 01:22 pm ET

The Law Offices of Frank R. Cruz Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ:

Apr 09, 2024 07:55 pm ET

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

NEW YORK, April 9, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT) and reminds investors of the June 4, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Apr 09, 2024 07:49 pm ET

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, April 9, 2024 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ: CKPT) and certain of its officers.

Apr 09, 2024 04:37 pm ET

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Apr 09, 2024 12:45 pm ET

Class Action Lawsuit Filed on Behalf of Checkpoint Therapeutics, Inc. (CKPT) Investors – Nationally Ranked Investors’ Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant Losses to C

A shareholder class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose...

Apr 09, 2024 11:50 am ET

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CKPT

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 4, 2024.

Apr 08, 2024 09:00 pm ET

CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Checkpoint Therapeutics, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) in the United States...

Apr 08, 2024 04:51 pm ET

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Checkpoint Therapeutics, Inc. (CKPT) Investors

(GLOBENEWSWIRE)—The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired Checkpoint Therapeutics, Inc. (“Checkpoint” or...

Apr 08, 2024 01:22 pm ET

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Checkpoint Therapeutics, Inc. (CKPT)

Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Checkpoint...

Apr 08, 2024 11:49 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – CKPT

Apr 08, 2024 10:54 am ET

Class Action Lawsuit Filed on Behalf of Checkpoint Therapeutics, Inc. (CKPT) Investors – Nationally Ranked Investors’ Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant Losses to C

Apr 07, 2024 11:21 pm ET

Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against Checkpoint Therapeutics, Inc. (CKPT)

Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) securities between March 10, 2021 and December 15, 2023....

Apr 05, 2024 09:12 pm ET

Pomerantz Law Firm Announces the Filing of a Class Action Against Checkpoint Therapeutics, Inc. and Certain Officers - CKPT

NEW YORK, April 5, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 24-cv-02613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Checkpoint securities between March 10, 2021 and December 15, 2023, both dates inclusive (the "Class Period"), seeking to recover d

Mar 22, 2024 08:30 am ET

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights. James F....

Mar 18, 2024 08:00 am ET

Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive...

Jan 29, 2024 08:00 am ET

Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement with a single healthcare-dedicated institutional investor for...

Jan 11, 2024 08:15 am ET

Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the B....

Jan 10, 2024 04:22 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Checkpoint Therapeutics, Inc. - CKPT

Pomerantz LLP is investigating claims on behalf of investors of Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....

Jan 06, 2024 10:30 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Checkpoint Therapeutics, Inc. - CKPT

NEW YORK, Jan. 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Jan 02, 2024 05:00 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Checkpoint Therapeutics, Inc. - CKPT

Dec 22, 2023 04:22 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Checkpoint Therapeutics, Inc. - CKPT

Pomerantz LLP is investigating claims on behalf of Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...

Dec 19, 2023 04:48 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Checkpoint Therapeutics, Inc. - CKPT

NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Dec 18, 2023 07:00 am ET

U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for the cosibelimab biologic license application (“BLA”) for the treatment...

Dec 05, 2023 08:30 am ET

Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued a new patent (U.S. Patent No. 11,834,505)...

Nov 13, 2023 05:00 pm ET

Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2023, and recent corporate highlights. “The...

Oct 18, 2023 08:30 am ET

Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the publication of results from the multicenter, multiregional, pivotal trial evaluating cosibelimab, a...

Oct 02, 2023 12:53 pm ET

Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding (i) Series A warrants...

Sep 21, 2023 08:30 am ET

Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference

Sep 06, 2023 08:30 am ET

Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023 04:15 pm ET

Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2023, and recent corporate highlights. “We continue...

Aug 14, 2023 04:01 pm ET

Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced...

Aug 02, 2023 09:31 am ET

Thinking about buying stock in Innoviz Technologies, 22nd Century Group, SmileDirectClub, Checkpoint Therapeutics, or View, Inc.?

NEW YORK, Aug. 2, 2023 /PRNewswire/ --InvestorsObserver issues critical PriceWatch Alerts for INVZ, XXII, SDC, CKPT, and VIEW.

Jul 31, 2023 08:00 am ET

Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,236,248 shares...

Jul 27, 2023 07:00 am ET

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced new, longer-term data for cosibelimab from its pivotal studies in locally advanced and metastatic cutaneous...

Jun 28, 2023 08:00 am ET

Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new pharmacokinetic (“PK”) modeling data on cosibelimab supporting the extension to an every-three-week...

May 23, 2023 08:30 am ET

Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,256,269 shares...

May 15, 2023 04:15 pm ET

Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2023, and recent corporate highlights. “The first...

May 15, 2023 04:01 pm ET

Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Mar 31, 2023 08:00 am ET

Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,700,000 shares...

Mar 30, 2023 08:00 pm ET

Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Mar 30, 2023 04:10 pm ET

Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights

Mar 02, 2023 07:00 am ET

Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for filing the Biologics License Application...

Feb 21, 2023 08:00 am ET

Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jan 17, 2023 08:30 am ET

Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference

Jan 04, 2023 08:00 am ET

Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the submission of a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”)...

Dec 15, 2022 08:00 am ET

Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 05, 2022 04:30 pm ET

Checkpoint Therapeutics Announces Reverse Stock Split

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it will effect a 1-for-10 reverse stock split of its issued and outstanding common stock. Checkpoint...

Nov 08, 2022 04:30 pm ET

Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Sep 22, 2022 08:30 am ET

Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor...

Sep 08, 2022 08:15 am ET

Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences

Aug 12, 2022 08:00 am ET

Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2022, and recent corporate highlights. James F....

Jun 16, 2022 07:30 am ET

Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced positive interim efficacy results from its registration-enabling clinical trial evaluating its anti-PD-L1...

Jun 06, 2022 04:30 pm ET

Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the presentation of data from its pivotal trial of cosibelimab in metastatic cutaneous squamous cell carcinoma...

May 19, 2022 08:30 am ET

Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

May 13, 2022 08:30 am ET

Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency

Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has received Pediatric Investigation Plan (PIP) product-specific waivers from the European Medicines...

May 12, 2022 04:30 pm ET

Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2022 and recent corporate highlights. James F....

Apr 28, 2022 08:00 am ET

Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the results of its pivotal trial of cosibelimab in metastatic cutaneous squamous cell carcinoma (cSCC)...

Apr 04, 2022 08:15 am ET

Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that members of Checkpoint’s management team will participate in the two-day Fortress Biotech (“Fortress”)...

Apr 01, 2022 08:30 am ET

Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced a...

Mar 28, 2022 07:30 am ET

Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2021 and recent corporate highlights. James F....

Jan 25, 2022 04:30 pm ET

Checkpoint Therapeutics to Participate in the B. Riley Securities’ Virtual Oncology Conference

Jan 25, 2022 07:30 am ET

Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced positive topline results from its registration-enabling clinical trial evaluating the safety and efficacy of...

Dec 08, 2021 08:30 am ET

Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the initiation of the CONTERNO study, a global, randomized Phase 3 trial of cosibelimab in combination with...

Nov 04, 2021 04:30 pm ET

Checkpoint Therapeutics Reports Third Quarter 2021 Financial Results

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2021. James F. Oliviero, President and Chief...

Sep 22, 2021 08:30 am ET

Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

Sep 09, 2021 08:30 am ET

Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences

Aug 05, 2021 04:30 pm ET

Checkpoint Therapeutics Reports Second Quarter 2021 Financial Results

Jul 08, 2021 08:30 am ET

Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference

Jun 09, 2021 08:30 am ET

Thinking about buying stock in Aethlon Medical, Checkpoint Therapeutics, ContextLogic, Clean Energy Fuels, or Solid Biosciences?

NEW YORK, June 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AEMD, CKPT, WISH, CLNE, and SLDB.

May 12, 2021 08:00 am ET

Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the completion of enrollment for the metastatic cutaneous squamous cell carcinoma (“cSCC”) cohort in its...

May 06, 2021 04:15 pm ET

Checkpoint Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

Mar 09, 2021 04:30 pm ET

Checkpoint Therapeutics Reports Full-Year 2020 Financial Results and Recent Corporate Highlights

Mar 04, 2021 08:00 am ET

Checkpoint Therapeutics to Participate in H.C. Wainwright Global Life Sciences Virtual Conference

Mar 01, 2021 08:30 am ET

Checkpoint Therapeutics Announces Formation of Scientific Advisory Board

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the formation of an independent Scientific Advisory Board comprising leaders in the fields of immunotherapy,...

Jan 06, 2021 08:30 am ET

Checkpoint Therapeutics to Participate in Three January 2021 Virtual Investor Conferences

Nov 09, 2020 08:00 am ET

Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced updated interim results from the ongoing global, open-label, multicohort Phase 1 clinical trial of its...

Nov 04, 2020 04:25 pm ET

Checkpoint Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today...

Nov 02, 2020 06:00 am ET

Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab

INCHEON, South Korea and NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Samsung Biologics Co., Ltd. ("Samsung Biologics") (KRX: 207940.KS) and Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), today announced the expansion of a long-term manufacturing partnership for Checkpoint's anti-PD-L1 antibody, cosibelimab. Building upon an existing contract manufacturing agreement entered into in 2017, Samsung Biologics will provide additional commercial-scale drug substance manufacturing for Checkpoint. Under the new agreement, Samsung Biologics will commence manufacturing in 2021 in Plant 1.

Sep 17, 2020 05:27 pm ET

Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering

Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under...

Sep 17, 2020 06:30 am ET

Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Sep 10, 2020 08:00 am ET

Checkpoint Therapeutics to Participate in Three September 2020 Virtual Investor Conferences

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James F. Oliviero, President and Chief Executive Officer, will participate in three virtual investor...

Aug 17, 2020 08:00 am ET

Checkpoint Therapeutics to Present at Virtual Corporate Access Summit Hosted by B. Riley FBR on Wednesday, August 19, 2020

Aug 12, 2020 07:30 am ET

Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today...

Aug 05, 2020 04:30 pm ET

Checkpoint Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

Jul 27, 2020 07:30 am ET

Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration-Enabling Trial at ESMO Virtual Congress 2020

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that an abstract highlighting updated interim safety and efficacy data from the ongoing...

Jul 20, 2020 09:31 am ET

Thinking about buying stock in iBio Inc, Idera Pharmaceuticals, PDS Biotechnology, Checkpoint Therapeutics, or Norwegian Cruise Line Holdings?

NEW YORK, July 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IBIO, IDRA, PDSB, CKPT, and NCLH.

May 22, 2020 08:30 am ET

Checkpoint Therapeutics to Host Virtual Annual Meeting of Stockholders

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it will host the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”) virtually due to...

May 06, 2020 04:30 pm ET

Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

Apr 27, 2020 07:00 am ET

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Checkpoint Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims

Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT). If you are a shareholder of Checkpoint Therapeutics, Inc. and wish to receive...

Apr 21, 2020 08:00 am ET

Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Patent and Trademark Office has issued a composition of matter patent for cosibelimab (formerly...

Mar 11, 2020 04:15 pm ET

Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today...

Jan 13, 2020 08:15 am ET

Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that feedback from the U.S. Food and Drug Administration (“FDA”) has confirmed the company’s plan to submit...

Nov 20, 2019 09:20 am ET

Checkpoint Therapeutics Announces Pricing of Public Offering of Common Stock

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the pricing of its previously announced underwritten public offering. Checkpoint is offering 13,400,000...

Nov 19, 2019 04:01 pm ET

Checkpoint Therapeutics Announces Proposed Public Offering of Common Stock

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an...

Nov 08, 2019 07:30 am ET

Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new pharmacokinetic and target occupancy modeling data for cosibelimab (formerly referred to as CK-301)...

Nov 07, 2019 04:30 pm ET

Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immunotherapy and targeted oncology company, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2019. James F....

Sep 30, 2019 07:30 am ET

Checkpoint Therapeutics Announces Presentation of Positive Interim Clinical Results for Anti-PD-L1 Cosibelimab at the European Society for Medical Oncology (ESMO) Congress 2019

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today...

Sep 26, 2019 08:30 am ET

Checkpoint Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

Sep 16, 2019 07:30 am ET

Checkpoint Therapeutics Announces Data Presentation at the European Society for Medical Oncology (ESMO) Congress 2019

Sep 04, 2019 08:30 am ET

Checkpoint Therapeutics to Present at September 2019 Investor Conferences

Aug 08, 2019 04:30 pm ET

Checkpoint Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

Jul 01, 2019 08:30 am ET

Checkpoint Therapeutics Added to Russell 2000® Index

May 09, 2019 05:00 pm ET

Checkpoint Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

May 01, 2019 07:30 am ET

Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab

>- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today...

Apr 03, 2019 08:30 am ET

Checkpoint Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

Mar 15, 2019 07:30 am ET

Checkpoint Therapeutics Reports Full-Year 2018 Financial Results and Recent Corporate Highlights

Mar 13, 2019 08:30 am ET

Checkpoint Therapeutics Announces Issuance of Two New Patents for EGFR Inhibitor CK-101

Jan 07, 2019 08:30 am ET

Checkpoint Therapeutics Initiates Registrational Development Programs for Anti-PD-L1 Antibody CK-301

Nov 02, 2018 08:00 am ET

Checkpoint Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

Oct 16, 2018 08:00 am ET

Checkpoint Therapeutics Appoints Christian Béchon to its Board of Directors

Sep 27, 2018 08:00 am ET

Checkpoint Therapeutics to Present at Ladenburg Thalmann 2018 Healthcare Conference

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a Fortress Biotech (NASDAQ: FBIO) company, today announced that James F. Oliviero, President and Chief Executive Officer of Checkpoint, will present a company overview at the Ladenburg...

Sep 25, 2018 08:00 am ET

Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-101

Sep 06, 2018 07:30 am ET

Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101

Aug 30, 2018 08:00 am ET

Checkpoint Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

Aug 13, 2018 08:00 am ET

Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer

Aug 07, 2018 04:30 pm ET

Checkpoint Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

Jun 04, 2018 08:00 am ET

Checkpoint Therapeutics to Participate in June Investor Conferences

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today...

May 10, 2018 04:30 pm ET

Checkpoint Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today...

Apr 18, 2018 09:00 am ET

Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting

Data support the commencement of a first-in-human Phase 1 trial

Mar 21, 2018 08:00 am ET

Checkpoint Therapeutics Initiates Dose Expansion Portion of Phase 1 Trial of Anti-PD-L1 Antibody CK-301

CK-301 was safe and well tolerated in dose escalation portion of Phase 1 trial

Mar 15, 2018 04:05 pm ET

Checkpoint Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced financial results...

Mar 15, 2018 07:30 am ET

Checkpoint Therapeutics Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research Annual Meeting

Mar 13, 2018 07:45 am ET

Checkpoint Therapeutics to Participate in March Investor Conferences

NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that James...

Mar 08, 2018 09:00 am ET

Checkpoint Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (Nasdaq:CKPT), a Fortress Biotech (Nasdaq:FBIO) company, today announced the pricing of its previously announced underwritten public offering. Checkpoint is offering 4,600,000 shares of...

Mar 07, 2018 04:05 pm ET

Checkpoint Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (Nasdaq:CKPT), a Fortress Biotech (Nasdaq:FBIO) company, today announced that it is proposing to offer and sell, subject to market conditions, shares of its...

Feb 06, 2018 08:30 am ET

Checkpoint Therapeutics to Present at BIO CEO & Investor Conference

NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that James F. Oliviero, President and Chief Executive Officer, will present a company overview at the 2018 BIO...

Jan 03, 2018 07:30 am ET

Checkpoint Therapeutics to Present at Biotech Showcase™ 2018

NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that President and Chief Executive Officer James F. Oliviero will present a company overview at Biotech Showcase™ 2018...

Dec 14, 2017 07:30 am ET

Checkpoint Therapeutics to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018

NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access...

Oct 05, 2017 07:30 am ET

Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301

NEW YORK, Oct. 05, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that the first patient has been dosed in a Phase 1 clinical study evaluating the safety and tolerability of CK-301 in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers....

Sep 20, 2017 08:00 am ET

Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference

NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that James F. Oliviero, President and Chief Executive Officer of Checkpoint, will present a company overview at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 at 11 a.m. EDT. The conference will be held at the Sofitel Hotel in New York City....

Sep 11, 2017 08:30 am ET

Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer

NEW YORK, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CK-101 (also known as RX518), the Company’s third-generation epidermal growth-factor receptor (EGFR) inhibitor, for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC)....

Sep 05, 2017 08:00 am ET

Checkpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

NEW YORK, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that James F. Oliviero, President and Chief Executive Officer of Checkpoint, will present a company overview at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on Monday, September 11, 2017 at 10:50 a.m. EDT. The conference will be held at the Lotte New York Palace Hotel in New York City....

Jun 26, 2017 08:00 am ET

Checkpoint Therapeutics Commences Trading on the NASDAQ Capital Market

NEW YORK, June 26, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company focused on the acquisition, development and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers, today announced that its common stock will commence trading on the NASDAQ Capital Market under the symbol “CKPT” at the open of the U.S. financial markets today. Upon initiation of trading on NASDAQ, the Company’s common stock will cease trading on the OTCQX® Best Market....

Feb 28, 2017 08:00 am ET

Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lung Cancer Compound CK-101

NEW YORK, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (OTCQX:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that the U.S. Patent and Trademark Office has issued a composition of matter patent for CK-101 (also known as RX518), Checkpoint’s oral, third-generation epidermal growth factor receptor (EGFR) inhibitor product candidate under development for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC)....

You are here

Checkpoint Therapeutics Inc (OQ:CKPT)

Business Focus: Biotechnology & Medical Research